Sharon Bio-Medicine gets USFDA nod for API plant in Taloja

Image via Shutterstock
Sharon Bio-Medicine on Tuesday said it has received approval from the US health regulator for its API plant at Taloja in Maharashtra.

The company, however, said it cannot start supplying to the US market as its payment for generic drug user fee is pending.

In a BSE filing, Sharon Bio Medicine said it has "received the Establishment Inspection Reports from the US Food and Drug Administration (USFDA)".

The inspection was conducted during June 29, 2015 to July 7, 2015 at the Taloja plant, it added.

"The API (active pharmaceuticals ingredients) is now approved by USFDA," the company said.

It may be noted that the payment for Generic Drug User Fee is pending and therefore supply to the US cannot be done unless pending arrears are cleared, it said without disclosing details.

Shares of Sharon Bio Medicine were trading at Rs 10.16 in the afternoon trade, up 19.95 per cent on BSE.


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel